DOCSLIB.ORG

Head-First-Book.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Head-First-Book.Pdf Head First Copyright © 2017 David Tomen This book is intended to supplement, not replace, the advice of a trained health professional. If you know or suspect that you have a health problem, you should consult a health professional. The author and publisher specifically disclaim any liability, loss, or risk, personal or otherwise, that is incurred as a consequence, direct or indirectly, of the use and application of any of the contents of this book. All rights reserved. In accordance with the U.S. Copyright Act of 1976, the scanning, uploading, and electronic sharing of any part of this book without permission of the publisher constitute unlawful piracy and theft of the author’s intellectual property. If you would like to use material from the book (other than for review purposes), prior written permission must be obtained by contacting the publisher at [email protected]. Thank you for your support of the author’s rights. NootropicsExpert.com 2001 Atlantic Shores Boulevard, Hallandale Beach, FL 33009 First Edition: January 2017 Table of Contents Introduction 1 Top 7 Brain Hacking Principles 6 There is No “Magic Pill” 6 Dosage and Synergy 7 Start Slow and Low 8 Avoid Tolerance 9 Choosing the Right Nootropic 11 Stay Safe 12 Evaluating your Nootropic Stack 13 Your Brain is Part of a System 13 How Your Brain Works 15 Brain Architecture 15 Cognitive Architecture 16 Cerebral Cortex 17 The Gatekeepers 17 Neurons & Synapses 18 Cell Membranes 18 Brain Cell Signaling 19 Neurotransmitters 20 Glutamate 21 GABA 21 Acetylcholine 22 Dopamine 22 Epinephrine & Norepinephrine 23 Serotonin 23 Improve Your Memory with Nootropics 25 Types of Memory 25 List of Nootropics 28 Acetyl-L-Carnitine 28 Alpha GPC 33 Alpha-Lipoic Acid 38 Aniracetam 44 Artichoke Extract (Luteolin) 49 Ashwagandha 54 Bacopa Monnieri 60 Cat’s Claw 65 Choline Bitartrate 70 Choline Citrate 75 CDP-Choline (Citicoline) 81 Centrophenoxine 86 Coluracetam 91 Coenzyme Q10 (CoQ10) 96 Creatine 102 DHEA 108 DMAE 114 5-HTP 120 Forskolin 127 GABA 133 Ginkgo Biloba 138 Ginseng 143 Gotu Kola 150 Huperzine-A 155 Iodine 161 Kava 169 L-Carnosine 175 L-DOPA 181 Lemon Balm 186 L-Glutamine 191 Lion’s Mane 197 L-Theanine 202 Magnesium 208 Melatonin 213 N-Acetyl L-Cysteine 219 N-Acetyl L-Tyrosine 226 NADH 233 Nefiracetam 239 Nicotine 246 Noopept 252 Oat Straw 259 Oxiracetam 264 Phenibut 270 Phenylalanine 277 Phenylpiracetam 284 Phosphatidylcholine (PC) 290 Phosphatidylserine (PS) 295 Picamilon 302 Piperine 308 Piracetam 313 PQQ 320 Pramiracetam 326 Pterostilbene 332 Resveratrol 339 Rhodiola Rosea 346 SAM-e 353 St. John’s wort 360 Sulbutiamine 369 Tryptophan 375 Turmeric 383 Uridine Monophosphate 391 Vinpocetine 398 Vitamin B1 (Thiamine) 404 Vitamin B3 (Niacin) 411 Vitamin B5 (Pantothenic Acid) 420 Vitamin B6 (Pyridoxine) 427 Vitamin B8 (Inositol) 434 Vitamin B9 (Folate) 441 Vitamin B12 (Cobalamin) 448 Nootropic Stack Recommendations 456 Best Nootropics for Cognition, Thinking and Decision-Making 457 Best Nootropics for Memory 458 Best Nootropics for Depression & Anxiety 460 Best Nootropics for Energy (physical & mental) & Motivation 461 Best Nootropics for Brain Repair and Maintenance 463 How to Create the Best Nootropic Stack 465 The Most Effective Nootropic Stack for You 466 Your First Nootropic Stack 466 Nootropics for Memory 467 Nootropics for Anxiety and Depression 468 Nootropics for Energy and Motivation 470 Nootropics for Brain Repair and Maintenance 471 Conclusion 472 My Nootropic Stack 473 Nootropics Glossary 474 References 493 Introduction bout 5 years ago, I came home to our 4th floor condo after taking my A dog for her noon walk. Oreo is an 8-pound black Chihuahua with one white paw. Thus her name. We walk 3-times a day. And had done for the last 3 years since she was a puppy. Except this time, I came home for lunch and a couple of minutes later heard a knock at the door. Our neighbor from the 2nd floor had Oreo in her arms. And asked, “Is this your dog”? Somehow, Oreo and I were separated on the elevator coming home. And I hadn’t noticed she was missing when I walked through our door. Can you Draw a Clock? Losing my dog between the 1st and 4th floor was not a one-time, chance occurrence. I was diagnosed Adult ADD about 10 years ago. Up to then I had no idea why I had a problem with focus all my adult life. I bought and read dozens of self-help books on how to focus. Depression because I couldn’t focus. And lost promotions from yearly management reviews showing I wasn’t “focused”. My doctor prescribed Ritalin and it was like someone turned on the light switch in my brain. Several years after the ADD diagnosis I ended up in the ER. What my wife feared was a heart attack turned out to be hypothyroidism. A non-functioning thyroid came with chronic fatigue syndrome, severe brain fog, memory loss, fibromyalgia, chronic pain, and adrenal fatigue. We endured endless visits to specialists and renowned hospitals including the Cleveland Clinic. Along with episodes of not remembering dates and ap- pointments, a failing business, a crumbling marriage, doctors, endocrinologists, neuroscience specialists and therapists. Two unrelated neurologists tested me for dementia, and early-onset Al- zheimer’s disease. One of the tests was the “Mini-Mental State Exam”. The doctor asked a series of questions designed to test a range of everyday mental skills. The maximum MMSE score is 30 points. A score of 20 to 24 suggests mild 1 David Tomen dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia. I got 30 points on every test which meant I didn’t have dementia. Mini-cog During the mini-cog, a person is asked to complete two tasks: 1. Remember, and a few minutes later, repeat the names of three common objects. 2. Draw a face of a clock showing all 12 numbers in the right places and a time specified by the examiner. The results of this brief test can help a physician determine if further evalu- ation is needed.1 I’m a writer, and not an artist. But was able to draw a near perfect clock. So it was becoming increasingly clear that this was not not dementia, or Alzheimer’s. But clearly my brain was not working nearly as well as it should. The medical bills kept stacking up, and the doctors had all but given up. There was nothing wrong with me according to mainstream medicine. But my life was falling apart and I had to make a decision. Either figure this thing out. Or give up and die. I decided there must be a better way. Nootropics Saved My Life I’m a Virgo. And this means I’m very methodical in my approach to life. There had to be another answer to my cognitive problems. And thus began years of research and experimenting. I had to find out if there was an alternative way to beat severe brain fog, memory loss and depression. Ritalin helped me focus. But was not helping in the memory and thinking department. Years of searching websites, reading stacks of books, and combing through the forums. And little by little, I was able to get my brain working again. With determination and time, it was working better than ever before. With the right combination of supplements and lifestyle changes, I’ve been able to turn my life around. My business is more profitable than ever, my relation- ship is better than the day we got married, and my brain is firing on all cylinders. And I continue to tweak and refine every area of my brain and cognition. 2 HEAD FIRST Who This Book is For So if you’re dealing with ADHD. Or are not happy with your life because of brain fog, low energy, moodiness, difficulty sleeping, memory loss or just a general feeling of malaise… this book could be your way back. Nootropics and neuroscience are finally coming of age. Researchers and ordinary neurohackers like us are beginning to understand a lot about the brain. And we’ve found that several things follow from taking care of your head first. Your quality of life is tied to how well your brain functions. If you give your brain what it needs, and slow down brain aging, boost your memory and alertness so you can think faster on your feet, and your brain begins to function the way it was designed or better – everything changes. My life, and the lives of tens of thousands of neurohackers is certainly testa- ment to that! Think about this for a moment. You go to the dentist once a year to see how your teeth are doing. But you don’t think about going to your neurologist once a year to see how your brain is doing. Clearly your brain is more important than your teeth. You can get false teeth. But replacement brains are simply not yet available. One big lesson we have learned is your brain is not going to get better on its own. Researchers at Simon Fraser University in Canada studied 3,305 volunteers aged 16 to 44 years. They concluded that our brains start going south at age 24.2 This means that even if you’re living an optimal lifestyle, eating right, exercis- ing, getting enough sleep, and breathing clean air – your brain health on average starts to decline in your early 20’s. So this book is not just for neurohackers looking to tweak their brain for optimal performance. This book is for you if you want to do better in any area of your life.
Load more

Recommended publications
  • 4695389.Pdf (3.200Mb)
    Non-classical amine recognition evolved in a large clade of olfactory receptors The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Li, Qian, Yaw Tachie-Baffour, Zhikai Liu, Maude W Baldwin, Andrew C Kruse, and Stephen D Liberles. 2015. “Non-classical amine recognition evolved in a large clade of olfactory receptors.” eLife 4 (1): e10441. doi:10.7554/eLife.10441. http://dx.doi.org/10.7554/ eLife.10441. Published Version doi:10.7554/eLife.10441 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993622 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA RESEARCH ARTICLE Non-classical amine recognition evolved in a large clade of olfactory receptors Qian Li1, Yaw Tachie-Baffour1, Zhikai Liu1, Maude W Baldwin2, Andrew C Kruse3, Stephen D Liberles1* 1Department of Cell Biology, Harvard Medical School, Boston, United States; 2Department of Organismic and Evolutionary Biology, Museum of Comparative Zoology, Harvard University, Cambridge, United States; 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States Abstract Biogenic amines are important signaling molecules, and the structural basis for their recognition by G Protein-Coupled Receptors (GPCRs) is well understood. Amines are also potent odors, with some activating olfactory trace amine-associated receptors (TAARs). Here, we report that teleost TAARs evolved a new way to recognize amines in a non-classical orientation.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Neuroprotection in Alzheimer's Disease
    Chapter 8 Neuroprotection in Alzheimer’s Disease Introduction Alzheimer’s disease (AD) is a progressive degenerative disorder of the brain that begins with memory impairment and eventually progresses to dementia, physical impairment, and death. Patients develop various psychiatric and neurological signs during the course of the disease. The prevalence rates of dementia vary significantly in different countries, but range from 2.1 to 10.5%. AD is the most common type of dementia, accounting for 50–60% of all cases, and is described in detail in a special report on AD (Jain 2010). Several other types of dementias are considered in the differential diagnosis of AD and sometimes all the dementias are lumped together if the type is not known. Other well-known types of dementias are vascular dementia, dementia of aging, and dementia associated with HIV infection. The focus of this section is on AD and some other dementias will be described in Chap. 11. Pathomechanism of Alzheimer’s Disease Several factors that play a role in the etiology and pathogenesis of AD include the following: • Aging • Genetic risk factors • Amyloid precursor protein (APP) and beta-amyloid (Ab) accumulation with neural and vascular sequelae • Tau hyperphosphorylation • Membrane disturbances, phospholipid metabolism, and disruption of signal transduction • Inflammatory reactions and immunological disturbances • Environmental toxins: trace metals • Neurotransmitter defects and imbalances K.K. Jain, The Handbook of Neuroprotection, DOI 10.1007/978-1-61779-049-2_8, 337 © Springer Science+Business Media, LLC 2011 338 8 Neuroprotection in Alzheimer’s Disease • Neuroendocrine disturbances • Oxidative injury and free radicals • Disturbances in regulation and receptors of neurotrophic factors (NTFs) Such a large number of factors in the etiology of AD are responsible for the plethora of theories of cause of AD.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0314884 A1 Cheyene (43) Pub
    US 20140314884A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0314884 A1 Cheyene (43) Pub. Date: Oct. 23, 2014 (54) HEALTH SUPPLEMENT USING GUARANA A61E36/53 (2006.01) EXTRACT A613 L/455 (2006.01) (52) U.S. Cl. (71) Applicant: Shaahin Cheyene, Venice, CA (US) CPC ............... A61K 36/534 (2013.01); A61K 36/53 (2013.01); A61K 36/16 (2013.01); A61K 36/41 (72) Inventor: Shaahin Cheyene, Venice, CA (US) (2013.01); A6 IK3I/522 (2013.01); A61 K 3I/714 (2013.01); A61 K3I/455 (2013.01); (21) Appl. No.: 13/751,151 A6 IK3I/221 (2013.01); A61 K3I/685 (2013.01); A61 K3I/198 (2013.01); A61 K (22) Filed: Apr. 17, 2013 31/4375 (2013.01); A61K 31/439 (2013.01): A6 IK3I/05 (2013.01) Publication Classification USPC .......................................................... 424/745 (51) Int. Cl. (57) ABSTRACT A6 IK36/534 (2006.01) The current invention is a Supplement made from a combina A6 IK 36/6 (2006.01) tion of herbs, vitamins, amino acids which in the preferred A6 IK 36/4I (2006.01) embodiment is a 100% vegetarian liquid capsules that are A6 IK3I/522 (2006.01) ingested allow for rapid absorption. The components of the A6 IK3I/714 (2006.01) Supplement can be mint or menthol Such as peppermint or A6 IK3I/05 (2006.01) spearmint, Methyl B12 or B12, Niacin, Guarana, Dimethy A6 IK3I/22 (2006.01) laminoethanol, Acetyl-L-carnitine or ALCAR, Ocimum A6 IK3I/685 (2006.01) tenuiflorum, one or more teas Such as green tea, white tea or A6 IK3I/98 (2006.01) black tea, Ginkgo, Rhodiola rosea, phosphatidylserine, A6 IK3I/4375 (2006.01) Tyrosine, L-Alpha Glycerylphosphorylcholine, Citicoline A6 IK3I/439 (2006.01) (INN), Huperzine A, and Vinpocetine.
    [Show full text]
  • Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to That Obtained by Complex Environment Rearing
    Neuropsychopharmacology (2006) 31, 90–100 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to that Obtained by Complex Environment Rearing ,1 1 1 1 Keith J Murphy* , Andrew G Foley , Alan W O’Connell and Ciaran M Regan 1 Department of Pharmacology, Applied Neurotherapeutics Research Group, Conway Institute, University College Dublin, Belfield, Dublin, Ireland Recent data suggest that Alzheimer’s patients who discontinue treatment with cholinesterase inhibitors have a significantly delayed cognitive decline as compared to patients receiving placebo. Such observations suggest cholinesterase inhibitors to provide a disease- modifying effect as well as symptomatic relief and, moreover, that this benefit remains after drug withdrawal. Consistent with this suggestion, we now demonstrate that chronic administration of tacrine, nefiracetam, and deprenyl, drugs that augment cholinergic function, increases the basal frequency of dentate polysialylated neurons in a manner similar to the enhanced neuroplasticity achieved through complex environment rearing. While both drug-treated and complex environment reared animals continue to exhibit memory- associated activation of hippocampal polysialylated neurons, the magnitude is significantly reduced suggesting that such interventions induce a more robust memory pathway that can acquire and consolidate new information more efficiently. This hypothesis is
    [Show full text]
  • Rat Brain Phosphatidyl-N,N-Dimethylethanolamine Is Rich in Polyunsaturated Fatty Acids
    Journal oj Neurochemistry Raven Press. New York 10 1985 International Society for Neurochemistry Rat Brain Phosphatidyl-N,N-Dimethylethanolamine Is Rich in Polyunsaturated Fatty Acids Mariateresa Tacconi and Richard J. Wurtman Laboratory of Neuroendocrine Regulation, Department of Applied Biological Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, U.S.A. Abstract: Phosphatidyl - N,N - dimethylethanolamine analysis of its FAs (36.9 :t 1.8 g/g). The FAs in the PE (PDME), an intermediate in the formation of phosphati- and PC of rat brain synaptosomes were also analyzed; dylcholine (PC) by the sequential methylation of phos- too little PDME was present in synaptosomes to permit phatidylethanolamine (PE), was purified from rat brain similar analysis. The percentage of unsaturated FAs in- and its fatty acid (FA) composition compared with those synaptosomal PE was even higher (43.4 vs. 27.7) than that of brain PC and PE. The proportion of polyunsaturated in PE prepared from whole brain. Since synaptosomes fatty acids (PUFAs) in the PDME (29.8%) was similar to have a very high activity of phosphatidyl-N-methyltrans- that of PE (27.7%) and much greater than in PC (2.8%). ferase, the enzyme complex that methylates PE to form Like the PUFAs of PE, the major PUFAs found in PDME PC, this enzyme may serve, in nerve endings, to produce were arachidonic acid (20:4) and docosahexaenoic acid a particular pool of PC, rich in PUFAs, which may have (22:6). An isotopic method was developed to quantify the a distinct physiological function. Key Words: Fatty PDME purified from brain; a tritiated methyl group from acid composition - Phos phatid ylethanolamine-N -meth- CHJI was transferred to the PDME in the presence of yltransferase - Phosphatidyl - N,N - dimethylethanol- cyclohexylamine to form pH]PC, and the radioactivity of amine-Rat brain.
    [Show full text]
  • Biochemical Development of Surface Activity in Mammalian Lung. IV
    Pediat. Res. 6: 81-99 (1972) Developmental physiology lung hyaline membrane disease phospholipids infants respiratory distress syndrome lecithin surfactant Biochemical Development of Surface Activity in Mammalian Lung. IV. Pulmonary Lecithin Synthesis in the Human Fetus and Newborn and Etiology of the Respiratory Distress Syndrome Louis GLUCK1391, MARIE V. KULOVIGH, ARTHUR I. EIDELMAN, LEANDRO CORDERO, AND AIDA F. KHAZIN Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, California, USA Extract The surface-active complex lining alveoli in normal lung lowers surface tension on ex- piration, thus preventing alveolar collapse. Surface activity follows a developmental timetable. Infants with idiopathic respiratory distress syndrome (RDS) almost ex- clusively are prematurely born, and their lungs lack adequate surface activity and are deficient in the principal surface-active component, lecithin. This deficiency implies that RDS is a "disease of development," with fetal and neonatal timetables for lecithin synthesis. The biosynthesis of lung lecithin in the living human infant was studied by examining phospholipids in lung effluent (pharyngeal aspirates, mucus), which have identical phospholipids to those in lung lavage (alveolar wash). The fatty acid esters of isolated lecithin and phosphatidyl dimethylethanolamine (PDME) were examined. The fi-carbon fatty acids are indicators of the primary pathways of synthesis of lecithin: (1) a preponderance of palmitic acid signifying cytidine diphosphate choline (CDP-choline) + D-a,{3-diglyceride -+lecithin (choline incorporation pathway) and (2) a preponder- ance of myristic acid signifying phosphatidyl ethanolamine (PE) + 2 CH3 —»• PDME + CHZ —> lecithin (methylation pathway). Fetal lung of 18 and 20 weeks showed slight incorporation by GDP-choline pathway, absence of PDME, and almost no methylation.
    [Show full text]
  • 1 Doctor Recommended for Ear Ringing Relief
    6/17/2019 Amazon.com: Premium Brain Function Supplement – Memory, Focus, Clarity – Nootropic Booster with DMAE, Bacopa Monnieri, L-Glutamine, Multi… Skip to main content All Try Prime brain supplement Deliver to EN Hello, Sign in 0 Guilford 06437 Today's Deals Your Amazon.com Gift Cards Account & Lists Orders Try Prime Cart ‹ Back to results Premium Brain Function Supplement – Memory, Focus, Clarity Price: $18.95 ($0.32 / Count) $19.95 $1.00 (5%) – Nootropic Booster with DMAE, Bacopa Monnieri, L- FREE Shipping on orders over $25—or get FREE Two-Day Shipping with Amazon Prime 1,425 customer reviews | 82 answered questions Extra $1.00 Off Coupon on first Subscribe and Save order only. Details In Stock. Sold by Arazo Nutrition and Fulfilled by Amazon. Subscribe & Save 5% 15% $18.95 ($0.32 / Count) Save 5% now and up to 15% on auto- deliveries. Learn more Get it Tuesday, Jun 18 One-time Purchase $19.95 ($0.33 / Count) 1+ Qty: Deliver every: 1 1 month ( Most common ) Subscribe now Add to List About the product ★ SCIENTIFICALLY FORMULATED – We carefully combined just the right amount of 41 ingredients into a premium formula designed to boost your focus, memory, concentration Other Sellers on Amazon 2 new from $19.95 and clarity. Perfect for college students, busy moms and aging seniors over 50. ★ FOCUS, MEMORY & CLARITY – Brain Plus is an all-natural Nootropic, formulated to help $22.95 ($0.38 / Count) & FREE Shipping on eligible Add to Cart support memory and cognition. The perfect blend of ingredients will increase oxygen and orders.
    [Show full text]
  • Nutritional and Herbal Therapies for Children and Adolescents
    Nutritional and Herbal Therapies for Children and Adolescents A Handbook for Mental Health Clinicians Nutritional and Herbal Therapies for Children and Adolescents A Handbook for Mental Health Clinicians George M. Kapalka Associate Professor, Monmouth University West Long Branch, NJ and Director, Center for Behavior Modifi cation Brick, NJ AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA Copyright © 2010 Elsevier Inc. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (44) (0) 1865 843830; fax (44) (0) 1865 853333; email: [email protected]. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material
    [Show full text]
  • A Systematic Review of Performance-Enhancing Pharmacologicals and Biotechnologies in the Army
    Bond University Research Repository A systematic review of performance-enhancing pharmacologicals and biotechnologies in the Army Ko, Henry ; Hunter, K E; Scott, A M; Ayson, Mark; Willson, M L Published in: Journal of the Royal Army Medical Corps DOI: 10.1136/jramc-2016-000752 Licence: CC BY-NC Link to output in Bond University research repository. Recommended citation(APA): Ko, H., Hunter, K. E., Scott, A. M., Ayson, M., & Willson, M. L. (2018). A systematic review of performance- enhancing pharmacologicals and biotechnologies in the Army. Journal of the Royal Army Medical Corps, 164(3). https://doi.org/10.1136/jramc-2016-000752 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator. Download date: 06 Oct 2021 ABSTRACT Introduction: In 2015, the Australian Army commissioned a systematic review to assess the evidence on effectiveness and safety of pharmacological and biotechnological products for cognitive enhancement specifically in Army personnel. Methods: Searches for studies examining biotechnological and pharmacological products in Army populations were conducted in December 2015. Cochrane CENTRAL, MEDLINE, EMBASE, CINAHL and PsycINFO were searched; no date or language restrictions were applied. WHO’s International Clinical Trials Registry Platform and ClinicalTrials.gov were searched to identify ongoing trials. Studies meeting inclusion criteria were evaluated for risk of bias using the Cochrane Risk of Bias tool.
    [Show full text]
  • 1 Protective Effects of L-Alpha-Glycerylphosphorylcholine
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by SZTE Doktori Értekezések Repozitórium (SZTE Repository of Dissertations) Protective effects of L-alpha-glycerylphosphorylcholine on ischaemia-reperfusion- induced inflammatory reactions Tünde T őkés 1, Eszter Tuboly 1, Gabriella Varga 1, László Major 2, Miklós Ghyczy 3, József Kaszaki 1, Mihály Boros 1* 1Institute of Surgical Research, University of Szeged, Szeged, Hungary 2Department of Oral and Maxillofacial Surgery, University of Szeged, Szeged, Hungary 3Retired chemist, Cologne, Germany Corresponding author*: Name: Mihály Boros Address: University of Szeged, School of Medicine, Institute of Surgical Research, Pécsi u. 6. Szeged, H-6720, Hungary Phone: +36 62 545103 FAX: +36 62 545743 E-mail address: [email protected] TT and ET contributed equally to this work. 1 Abstract Purpose: Choline-containing dietary phospholipids, including phosphatidylcholine (PC), may function as anti-inflammatory substances, but the mechanism remains largely unknown. We investigated the effects of L-alpha-glycerylphosphorylcholine (GPC), a deacylated PC derivative, in a rodent model of small intestinal ischaemia-reperfusion (IR) injury. Methods: Anaesthetized Sprague-Dawley rats were divided into control, mesenteric IR (45 min mesenteric artery occlusion, followed by 180 min reperfusion), IR with GPC pretreatment (16.56 mg kg -1 GPC i.v., 5 min prior to ischaemia) or IR with GPC post- treatment (16.56 mg kg -1 GPC i.v., 5 min prior to reperfusion) groups. Macrohaemodynamics and microhaemodynamic parameters were measured; intestinal inflammatory markers (xanthine oxidoreductase activity, superoxide and nitrotyrosine levels) and liver ATP contents were determined. Results: The IR challenge reduced the intestinal intramural red blood cell velocity, increased the mesenteric vascular resistance, the tissue xanthine oxidoreductase activity, the superoxide production and the nitrotyrosine levels, and the ATP content of the liver was decreased.
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]